{
    "organizations": [],
    "uuid": "176be5e391c817da9992972c4ec604ca74516e63",
    "author": "",
    "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-pos/brief-catalyst-biosciences-announces-positive-top-line-data-from-phase-1-2-study-of-subcutaneous-cb-2679d-isu304-idUSFWN1PZ0YR",
    "ord_in_thread": 0,
    "title": "BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 9, 2018 / 12:57 PM / Updated 16 minutes ago BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304 Reuters Staff 1 Min Read \nFeb 9 (Reuters) - Catalyst Biosciences Inc: \n* CATALYST BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 1/2 STUDY OF SUBCUTANEOUS CB 2679D/ISU304 IN INDIVIDUALS WITH HEMOPHILIA B \n* CATALYST BIOSCIENCES INC - ALL INDIVIDUALS WITH SEVERE HEMOPHILIA IMPROVED TO MILD HEMOPHILIA ACTIVITY LEVELS AFTER ONLY SIX DAILY DOSES \n* CATALYST BIOSCIENCES - ‍RESULTS SUGGEST LONG-TERM DOSING OF SQ CB 2679D COULD MAINTAIN STABLE CLOTTING ACTIVITY IN HIGH-MILD HEMOPHILIA TO NORMAL RANGE​ \n* CATALYST BIOSCIENCES INC - ‍NO INHIBITORS TO CB 2679D OR FIX WERE INDUCED TO DATE​ \n* CATALYST BIOSCIENCES-‍1 SUBJECT HAD MODERATE ADVERSE EVENTS OF PAIN,ERYTHEMA,REDNESS AFTER FIRST 2 INJECTIONS, MILD RATING AFTER SUBSEQUENT INJECTIONS​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-09T14:57:00.000+02:00",
    "crawled": "2018-02-09T15:20:31.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "bioscience",
        "announces",
        "positive",
        "data",
        "phase",
        "study",
        "subcutaneous",
        "cb",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "catalyst",
        "bioscience",
        "inc",
        "catalyst",
        "bioscience",
        "announces",
        "positive",
        "data",
        "phase",
        "study",
        "subcutaneous",
        "cb",
        "individual",
        "hemophilia",
        "b",
        "catalyst",
        "bioscience",
        "inc",
        "individual",
        "severe",
        "hemophilia",
        "improved",
        "mild",
        "hemophilia",
        "activity",
        "level",
        "six",
        "daily",
        "dos",
        "catalyst",
        "bioscience",
        "suggest",
        "dosing",
        "sq",
        "cb",
        "2679d",
        "could",
        "maintain",
        "stable",
        "clotting",
        "activity",
        "hemophilia",
        "normal",
        "catalyst",
        "bioscience",
        "inc",
        "inhibitor",
        "cb",
        "2679d",
        "fix",
        "induced",
        "catalyst",
        "subject",
        "moderate",
        "adverse",
        "event",
        "pain",
        "erythema",
        "redness",
        "first",
        "injection",
        "mild",
        "rating",
        "subsequent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}